Nature of the Business - Additional Information (Details) $ / shares in Units, $ in Thousands |
1 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
|
Aug. 13, 2026
USD ($)
|
Oct. 28, 2025
shares
|
Oct. 31, 2025
USD ($)
$ / shares
shares
|
Jun. 30, 2026
USD ($)
|
Dec. 31, 2025
USD ($)
|
|
| Subsidiary, Sale of Stock [Line Items] | |||||
| Accumulated deficit | $ (481,380) | $ (360,520) | |||
| Cash, cash equivalents, and investments | $ 351,300 | ||||
| Description of reverse stock spilt | In October 2025, the Company effected a 1-for-16.8 reverse stock split of the Company's common stock. This also resulted in an adjustment to the conversion price for each series of the Company's redeemable convertible preferred stock, to the number of shares of common stock underlying outstanding restricted stock units, and to the exercise prices and number of shares of common stock underlying outstanding stock options. | ||||
| Reverse Stock Split conversion ratio | 0.0595 | ||||
| Common Stock | |||||
| Subsidiary, Sale of Stock [Line Items] | |||||
| Aggregate net proceeds received from IPO and option exercise | $ 261,600 | ||||
| Shares converted into common stock | shares | 25,412,974 | 25,412,974 | |||
| IPO | Common Stock | |||||
| Subsidiary, Sale of Stock [Line Items] | |||||
| Number of shares issued | shares | 16,962,500 | ||||
| Price per share | $ / shares | $ 17 | ||||
| Gross proceeds from issuance of common stock | $ 288,400 | ||||
| IPO | Non-Voting Common Stock | Common Stock | |||||
| Subsidiary, Sale of Stock [Line Items] | |||||
| Shares converted into common stock | shares | 2,727,511 | ||||
| Concurrent Private Placement | Common Stock | |||||
| Subsidiary, Sale of Stock [Line Items] | |||||
| Number of shares issued | shares | 476,707 | ||||
| Price per share | $ / shares | $ 17 | ||||
| Gross proceeds from issuance of common stock | $ 150,000 | $ 7,500 |